Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Vitamin Shoppe shrugs off DMAA warnings; Teva grows OTCs, transitions CEO; Reckitt’s Mucinex still ahead of private label; DSM nutrition still up from Martek acquisition; more Sales & Earnings In Brief.
You may also be interested in...
Reckitt pins hopes on health product line extensions; DSM girds for further European tumult with profit improvement program; operational efficiencies grow Vitamin Shoppe margin; Omega Protein fish oil yield plummets; Vitacost.com boosts proprietary offerings; more Sales & Earnings In Brief.
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.
Planned launches of generic Claritin-D, Mucinex and Prevacid 24HR are expected to help Perrigo reach 12% to 14% consumer health care growth in fiscal 2012. Opportunities to gain from J&J and Novartis OTC recalls likely are minimal going forward, the private labeler says on its Q2 earnings call.